Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5

Annalisa Trama, Laura Botta, Roberto Foschi, Andrea Ferrari, Charles Stiller, Emmanuel Desandes, Milena Maria Maule, Franco Merletti, Gemma Gatta, EUROCARE-5 Working Group, Paolo Giorgi Rossi

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Data from EUROCARE have consistently shown lower survival for adolescents and young adults (AYAs; aged 15-24 years) than for children (0-14 years) for most cancers that affect both groups, and modest survival improvements up to 2000-02. AYAs have longer survival than that of adults for most cancers. We used the latest definition of AYAs (aged 15-39 years) and provided estimates of 5-year relative survival for European AYAs with cancer diagnosed in 2000-07, compared with children and adults (40-69 years) with cancer, and assessed survival improvements over time.

METHODS: We analysed data from population-based cancer registries of 27 European countries participating in EUROCARE-5. We used the so-called complete method to estimate 5-year, population-weighted relative survival for 19 cancers affecting AYAs and children, and for 27 cancers affecting AYAs and adults. We assessed relative-survival differences between children versus AYAs, and between AYAs versus adults, using the Z test. We used the period approach to estimate 5-year relative survival over time for children and AYAs, and used a generalised linear model to model survival time trends (1999-2007) and to assess the significance of changes over time.

FINDINGS: We analysed 56 505 cancer diagnoses in children, 312 483 in AYAs, and 3 567 383 in adults. For all cancers combined, survival improved over time for AYAs (from 79% [95% CI 78·1-80·5] in 1999-2002 to 82% [81·1-83·3] in 2005-07; p<0·0001) and children (from 76% [74·7-77·1] to 79% [77·2-79·4]; p<0·0001). Survival improved significantly in children and AYAs for acute lymphoid leukaemia (p<0·0001) and non-Hodgkin lymphoma (p<0·0001 in AYAs and p=0·023 in children). Survival improved significantly in AYAs only for CNS tumours (p=0·0046), astrocytomas (p=0·040), and malignant melanomas (p<0·0001). Survival remained significantly worse in AYAs than in children for eight important cancers: acute lymphoid leukaemias, acute myeloid leukaemias, Hodgkin's lymphomas, non-Hodgkin lymphomas, astrocytomas, Ewing's sarcomas, and rhabdomyosarcomas (p<0·0001 in all cases), and osteosarcomas (p=0·011).

INTERPRETATION: Notwithstanding the encouraging results for some cancers, and overall, we showed poorer survival in AYAs than in children for the eight important cancers. Recent European initiatives to improve outcomes in AYAs might reduce the survival gap between children and AYAs, but this reduction can only be verified by future population-based studies.

FUNDING: Italian Ministry of Health, European Commission.

Original languageEnglish
Pages (from-to)896-906
Number of pages11
JournalThe Lancet Oncology
Volume17
Issue number7
DOIs
Publication statusPublished - Jul 2016

Fingerprint

Young Adult
Population
Neoplasms
Astrocytoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Non-Hodgkin's Lymphoma
Ewing's Sarcoma
Rhabdomyosarcoma
Osteosarcoma
Hodgkin Disease
Acute Myeloid Leukemia
Registries
Linear Models
Melanoma

Keywords

  • Journal Article

Cite this

Survival of European adolescents and young adults diagnosed with cancer in 2000-07 : population-based data from EUROCARE-5. / Trama, Annalisa; Botta, Laura; Foschi, Roberto; Ferrari, Andrea; Stiller, Charles; Desandes, Emmanuel; Maule, Milena Maria; Merletti, Franco; Gatta, Gemma; EUROCARE-5 Working Group ; Giorgi Rossi, Paolo.

In: The Lancet Oncology, Vol. 17, No. 7, 07.2016, p. 896-906.

Research output: Contribution to journalArticle

Trama, Annalisa ; Botta, Laura ; Foschi, Roberto ; Ferrari, Andrea ; Stiller, Charles ; Desandes, Emmanuel ; Maule, Milena Maria ; Merletti, Franco ; Gatta, Gemma ; EUROCARE-5 Working Group ; Giorgi Rossi, Paolo. / Survival of European adolescents and young adults diagnosed with cancer in 2000-07 : population-based data from EUROCARE-5. In: The Lancet Oncology. 2016 ; Vol. 17, No. 7. pp. 896-906.
@article{d98efd80900b4f359ee15150091c7bec,
title = "Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5",
abstract = "BACKGROUND: Data from EUROCARE have consistently shown lower survival for adolescents and young adults (AYAs; aged 15-24 years) than for children (0-14 years) for most cancers that affect both groups, and modest survival improvements up to 2000-02. AYAs have longer survival than that of adults for most cancers. We used the latest definition of AYAs (aged 15-39 years) and provided estimates of 5-year relative survival for European AYAs with cancer diagnosed in 2000-07, compared with children and adults (40-69 years) with cancer, and assessed survival improvements over time.METHODS: We analysed data from population-based cancer registries of 27 European countries participating in EUROCARE-5. We used the so-called complete method to estimate 5-year, population-weighted relative survival for 19 cancers affecting AYAs and children, and for 27 cancers affecting AYAs and adults. We assessed relative-survival differences between children versus AYAs, and between AYAs versus adults, using the Z test. We used the period approach to estimate 5-year relative survival over time for children and AYAs, and used a generalised linear model to model survival time trends (1999-2007) and to assess the significance of changes over time.FINDINGS: We analysed 56 505 cancer diagnoses in children, 312 483 in AYAs, and 3 567 383 in adults. For all cancers combined, survival improved over time for AYAs (from 79{\%} [95{\%} CI 78·1-80·5] in 1999-2002 to 82{\%} [81·1-83·3] in 2005-07; p<0·0001) and children (from 76{\%} [74·7-77·1] to 79{\%} [77·2-79·4]; p<0·0001). Survival improved significantly in children and AYAs for acute lymphoid leukaemia (p<0·0001) and non-Hodgkin lymphoma (p<0·0001 in AYAs and p=0·023 in children). Survival improved significantly in AYAs only for CNS tumours (p=0·0046), astrocytomas (p=0·040), and malignant melanomas (p<0·0001). Survival remained significantly worse in AYAs than in children for eight important cancers: acute lymphoid leukaemias, acute myeloid leukaemias, Hodgkin's lymphomas, non-Hodgkin lymphomas, astrocytomas, Ewing's sarcomas, and rhabdomyosarcomas (p<0·0001 in all cases), and osteosarcomas (p=0·011).INTERPRETATION: Notwithstanding the encouraging results for some cancers, and overall, we showed poorer survival in AYAs than in children for the eight important cancers. Recent European initiatives to improve outcomes in AYAs might reduce the survival gap between children and AYAs, but this reduction can only be verified by future population-based studies.FUNDING: Italian Ministry of Health, European Commission.",
keywords = "Journal Article",
author = "Annalisa Trama and Laura Botta and Roberto Foschi and Andrea Ferrari and Charles Stiller and Emmanuel Desandes and Maule, {Milena Maria} and Franco Merletti and Gemma Gatta and {EUROCARE-5 Working Group} and {Giorgi Rossi}, Paolo",
note = "Copyright {\circledC} 2016 Elsevier Ltd. All rights reserved.",
year = "2016",
month = "7",
doi = "10.1016/S1470-2045(16)00162-5",
language = "English",
volume = "17",
pages = "896--906",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "7",

}

TY - JOUR

T1 - Survival of European adolescents and young adults diagnosed with cancer in 2000-07

T2 - population-based data from EUROCARE-5

AU - Trama, Annalisa

AU - Botta, Laura

AU - Foschi, Roberto

AU - Ferrari, Andrea

AU - Stiller, Charles

AU - Desandes, Emmanuel

AU - Maule, Milena Maria

AU - Merletti, Franco

AU - Gatta, Gemma

AU - EUROCARE-5 Working Group

AU - Giorgi Rossi, Paolo

N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.

PY - 2016/7

Y1 - 2016/7

N2 - BACKGROUND: Data from EUROCARE have consistently shown lower survival for adolescents and young adults (AYAs; aged 15-24 years) than for children (0-14 years) for most cancers that affect both groups, and modest survival improvements up to 2000-02. AYAs have longer survival than that of adults for most cancers. We used the latest definition of AYAs (aged 15-39 years) and provided estimates of 5-year relative survival for European AYAs with cancer diagnosed in 2000-07, compared with children and adults (40-69 years) with cancer, and assessed survival improvements over time.METHODS: We analysed data from population-based cancer registries of 27 European countries participating in EUROCARE-5. We used the so-called complete method to estimate 5-year, population-weighted relative survival for 19 cancers affecting AYAs and children, and for 27 cancers affecting AYAs and adults. We assessed relative-survival differences between children versus AYAs, and between AYAs versus adults, using the Z test. We used the period approach to estimate 5-year relative survival over time for children and AYAs, and used a generalised linear model to model survival time trends (1999-2007) and to assess the significance of changes over time.FINDINGS: We analysed 56 505 cancer diagnoses in children, 312 483 in AYAs, and 3 567 383 in adults. For all cancers combined, survival improved over time for AYAs (from 79% [95% CI 78·1-80·5] in 1999-2002 to 82% [81·1-83·3] in 2005-07; p<0·0001) and children (from 76% [74·7-77·1] to 79% [77·2-79·4]; p<0·0001). Survival improved significantly in children and AYAs for acute lymphoid leukaemia (p<0·0001) and non-Hodgkin lymphoma (p<0·0001 in AYAs and p=0·023 in children). Survival improved significantly in AYAs only for CNS tumours (p=0·0046), astrocytomas (p=0·040), and malignant melanomas (p<0·0001). Survival remained significantly worse in AYAs than in children for eight important cancers: acute lymphoid leukaemias, acute myeloid leukaemias, Hodgkin's lymphomas, non-Hodgkin lymphomas, astrocytomas, Ewing's sarcomas, and rhabdomyosarcomas (p<0·0001 in all cases), and osteosarcomas (p=0·011).INTERPRETATION: Notwithstanding the encouraging results for some cancers, and overall, we showed poorer survival in AYAs than in children for the eight important cancers. Recent European initiatives to improve outcomes in AYAs might reduce the survival gap between children and AYAs, but this reduction can only be verified by future population-based studies.FUNDING: Italian Ministry of Health, European Commission.

AB - BACKGROUND: Data from EUROCARE have consistently shown lower survival for adolescents and young adults (AYAs; aged 15-24 years) than for children (0-14 years) for most cancers that affect both groups, and modest survival improvements up to 2000-02. AYAs have longer survival than that of adults for most cancers. We used the latest definition of AYAs (aged 15-39 years) and provided estimates of 5-year relative survival for European AYAs with cancer diagnosed in 2000-07, compared with children and adults (40-69 years) with cancer, and assessed survival improvements over time.METHODS: We analysed data from population-based cancer registries of 27 European countries participating in EUROCARE-5. We used the so-called complete method to estimate 5-year, population-weighted relative survival for 19 cancers affecting AYAs and children, and for 27 cancers affecting AYAs and adults. We assessed relative-survival differences between children versus AYAs, and between AYAs versus adults, using the Z test. We used the period approach to estimate 5-year relative survival over time for children and AYAs, and used a generalised linear model to model survival time trends (1999-2007) and to assess the significance of changes over time.FINDINGS: We analysed 56 505 cancer diagnoses in children, 312 483 in AYAs, and 3 567 383 in adults. For all cancers combined, survival improved over time for AYAs (from 79% [95% CI 78·1-80·5] in 1999-2002 to 82% [81·1-83·3] in 2005-07; p<0·0001) and children (from 76% [74·7-77·1] to 79% [77·2-79·4]; p<0·0001). Survival improved significantly in children and AYAs for acute lymphoid leukaemia (p<0·0001) and non-Hodgkin lymphoma (p<0·0001 in AYAs and p=0·023 in children). Survival improved significantly in AYAs only for CNS tumours (p=0·0046), astrocytomas (p=0·040), and malignant melanomas (p<0·0001). Survival remained significantly worse in AYAs than in children for eight important cancers: acute lymphoid leukaemias, acute myeloid leukaemias, Hodgkin's lymphomas, non-Hodgkin lymphomas, astrocytomas, Ewing's sarcomas, and rhabdomyosarcomas (p<0·0001 in all cases), and osteosarcomas (p=0·011).INTERPRETATION: Notwithstanding the encouraging results for some cancers, and overall, we showed poorer survival in AYAs than in children for the eight important cancers. Recent European initiatives to improve outcomes in AYAs might reduce the survival gap between children and AYAs, but this reduction can only be verified by future population-based studies.FUNDING: Italian Ministry of Health, European Commission.

KW - Journal Article

U2 - 10.1016/S1470-2045(16)00162-5

DO - 10.1016/S1470-2045(16)00162-5

M3 - Article

C2 - 27237614

VL - 17

SP - 896

EP - 906

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 7

ER -